Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543439 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 66
- Enrollment target
NCT00543439 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 66 participants.
The verdict
NCT00543439, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the effectiveness, safety, and pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are younger than 6 years of age, with severe or moderately severe hemophilia A.
Interventions
- BIOLOGICAL Moroctocog alfa (AF-CC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2007-12 |
| Est. Completion | 2018-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543439
The ClinicalTrials.gov registry entry for NCT00543439 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Moroctocog alfa (AF-CC) is the first listed.
NCT00543439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00543439 about?
NCT00543439 is a clinical study titled "Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII". The purpose of this research study is to determine the effectiveness, safety, and pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are younger than 6 years of age, with severe or moderately severe hemophilia A.
What is the current status of trial NCT00543439?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 66 participants. The study started on 2007-12. Estimated completion is 2018-04.
What interventions are being tested in trial NCT00543439?
The interventions under investigation include: Moroctocog alfa (AF-CC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00543439?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.